Vyxeos Liposomal is the first chemotherapy to significantly increase median overall survival (OS)
vs conventional chemotherapy** in patients with high-risk* AML1
(KM-estimated median OS: Vyxeos Liposomal, 9.56 months; conventional chemotherapy, 5.96 months
(HR: 0.69, 95% CI: 0.52-0.90, p=0.005 [2-sided])1,2)
Vyxeos Liposomal is indicated for the treatment of adults with newly diagnosed,
therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC)2
Important notice: This site has been created for healthcare professionals only. By entering this site, you are confirming that you are a European healthcare professional. This site contains promotional information.
I CONFIRM THAT I AM A EUROPEAN HEALTHCARE PROFESSIONAL
I AM A UK HEALTHCARE PROFESSIONAL
I AM A US HEALTHCARE PROFESSIONAL
I AM NOT A HEALTHCARE PROFESSIONAL
Please note that this information is intended for healthcare professionals in the UK
Please note that this information is intended for healthcare professionals in the US only
For more information:
By clicking here you will be taken to the European Medicines Agency’s external website
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly through your national medicines side effect reporting system or to Jazz Pharmaceuticals AEreporting@jazzpharma.com. By reporting side effects, you can help provide more information on the safety of this medicine.